コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 arrhea) and/or alter chloride ion secretion (secretory diarrhea).
2 esting an important role for this pathway in secretory diarrhea.
3 a common feature of many diseases including secretory diarrhea.
4 nd can thereby be a potent target to prevent secretory diarrhea.
5 and diarrheal diseases, eg, cystic fibrosis, secretory diarrhea.
6 accumulation in a closed-loop mouse model of secretory diarrhea.
7 nockout mice are more prone to CFTR-mediated secretory diarrhea.
8 rders such as inflammatory bowel disease and secretory diarrhea.
9 -labile or heat-stable toxins which induce a secretory diarrhea.
10 pivotal role in cholera toxin (CTX)-induced secretory diarrhea.
11 ium transport are not known to be a cause of secretory diarrhea.
12 une-mediated apoptosis and limiting chloride secretory diarrhea.
13 secretomotor neurons, may lead to neurogenic secretory diarrhea.
14 m, and water in the model of chronic osmotic-secretory diarrhea.
15 g to the MVID clinical phenotype of neonatal secretory diarrhea.
16 a, which deregulates this pathway and causes secretory diarrhea.
17 y of (R)-BPO-27 for therapy of CFTR-mediated secretory diarrheas.
18 ociated diseases such as cystic fibrosis and secretory diarrheas.
19 disease and reduce intestinal fluid loss in secretory diarrheas.
20 antisecretory drugs for enterotoxin-mediated secretory diarrheas.
21 ing intestinal fluid losses in CaCC-mediated secretory diarrheas.
22 e compounds may provide a unique therapy for secretory diarrheas.
23 et in the intestinal mucosa for treatment of secretory diarrheas.
24 ay thus reduce fluid secretion in infectious secretory diarrheas.
25 g intestinal fluid loss in cholera and other secretory diarrheas.
26 onditions including cholera [5, 6] and other secretory diarrheas [7] as well as polycystic kidney dis
27 mportant in the complexities associated with secretory diarrhea and also in attempting to develop tre
29 neurons is basic to understanding neurogenic secretory diarrhea and constipation and therapeutic stra
31 table enterotoxins (STs), a leading cause of secretory diarrhea, are a major cause of morbidity and m
37 ntial utility of (R)-BPO-27 for treatment of secretory diarrheas caused by cholera and Escherichia co
38 toxin (ctxAB), the main cause of the profuse secretory diarrhea characteristic of cholera, are encode
40 ble enterotoxins (STa), which cause an acute secretory diarrhea, have been suggested to mediate their
41 were the exclusive driving force for severe secretory diarrhea in a patient with colonic pseudo-obst
44 cleotide and/or Ca(2+) signaling pathways in secretory diarrheas increases the conductance of Cl(-) c
50 eptor subtype in the mediation of neurogenic secretory diarrhea, motility abnormality, and abdominal
53 e-phenolphthalein to produce chronic osmotic-secretory diarrhea or luminally exposed to 10 mmol/L the
54 se potential therapeutic indications include secretory diarrheas, polycystic kidney disease, and grow
56 s an AB(5) toxin responsible for the profuse secretory diarrhea resulting from Vibrio cholerae infect
59 render them more resistant to CFTR-mediated secretory diarrhea than Nherf2(+/+) mice in murine colit
60 study reveals an ion transport mechanism of secretory diarrhea that has not been previously apprecia
61 of our report is to describe a patient with secretory diarrhea that was mediated by excess intestina
62 of electrogenic Cl- secretion (the basis of secretory diarrhea) via apical A2b adenosine receptors.
63 mune enteropathy is characterized by chronic secretory diarrhea, villous atrophy, associated autoanti
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。